NMN and NR Titration in Hepatic Impairment: What Women Need to Know

Why Hepatic Impairment Changes Everything for NMN and NR

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors. Both are converted to NAD+ through pathways that run primarily through the liver. When liver function is compromised, that conversion pathway slows, metabolites may accumulate, and the standard dosing logic breaks down entirely.

The liver processes NMN and NR via the Preiss-Handler pathway and the salvage pathway, with nicotinamide (NAM) as a key intermediate. Research in mice with hepatic steatosis showed that NMN supplementation reduced fat accumulation and improved mitochondrial function, but this does not translate cleanly to dosing guidance in humans with liver disease. Animal data is not a clinical protocol.

For women specifically, this matters because the conditions most commonly associated with hepatic impairment overlap heavily with female-pattern metabolic disease: non-alcoholic fatty liver disease (NAFLD) linked to PCOS, metabolic dysfunction-associated steatotic liver disease (MASLD) in perimenopause, and autoimmune hepatitis, which is three to four times more common in women than men.

How Liver Impairment Grading Affects Your Starting Point

Clinicians use the Child-Pugh score or MELD score to grade hepatic impairment. No published RCT has stratified NMN or NR dosing by these scores, so the following is clinical extrapolation based on general pharmacokinetic principles and the available safety data from healthy-adult trials.

• Child-Pugh A (mild impairment): A cautious starting dose of 50 mg/day of NMN or NR is reasonable, with slow escalation and liver enzyme monitoring every four weeks.
• Child-Pugh B (moderate impairment): Deferring supplementation until underlying liver disease is stabilized is the safer path. If a specialist approves, 50 mg/day with monthly labs is a minimum requirement.
• Child-Pugh C (severe impairment): NMN and NR should not be used without hepatology oversight. The nicotinamide load could stress an already-compromised methylation capacity.

The Methylation Burden Problem

One concern specific to higher NMN and NR doses is the methyl-group demand. As NAD+ is produced and broken down, nicotinamide is exported and must be methylated to 1-methylnicotinamide (MeNAM) before excretion. This process consumes S-adenosyl methionine (SAM). In a woman with cirrhosis or significant fibrosis, SAM synthesis is already impaired. Pushing through 500 to 1,000 mg/day of an NAD+ precursor could theoretically worsen methylation capacity, though direct human evidence for this is lacking at therapeutic NAD+ precursor doses.

What the Clinical Trial Data Actually Show

No RCT has studied NMN or NR titration specifically in people with hepatic impairment. The safety data we have comes from healthy adults or adults with specific metabolic conditions, and it skews male.

NMN Human Safety Trials

The first-in-human NMN oral bioavailability study by Irie et al. (2020) tested single doses of 100 mg, 250 mg, and 500 mg in 10 healthy men and found no clinically significant changes in liver enzymes, blood pressure, or heart rate at any dose. All participants were men. The trial did not assess repeated dosing or impaired hepatic function.

A 2023 randomized controlled trial by Yi et al. studied 300 mg/day NMN for 60 days in middle-aged adults and reported no elevation in ALT or AST beyond normal variation. Women made up approximately 45% of participants, but the trial excluded anyone with abnormal baseline liver enzymes. This exclusion is common and means people with hepatic impairment have essentially zero representation in the NMN RCT database.

NR Human Safety Trials

The Elysium Health-sponsored Trammell et al. (2016) trial gave NR at 100 mg and 300 mg daily for six weeks to 12 healthy adults. NAD+ rose by approximately 40 to 50% in whole blood at 300 mg. No hepatotoxicity was observed, but the sample had no liver disease and was too small to detect rare adverse events.

ChromaDex-sponsored data reviewed in Conze et al. (2019) assessed NR doses up to 2,000 mg/day in healthy adults for eight weeks. Liver enzymes remained within reference ranges. Again, hepatic impairment was an exclusion criterion.

The honest summary: every published NMN and NR RCT excludes the population this article is written for. The doses studied are safe in healthy livers. Safe-in-healthy-liver data cannot be extrapolated to impaired livers without caution.

What We Can Borrow From Niacin Pharmacology

NMN and NR ultimately increase systemic nicotinamide. High-dose niacin (nicotinic acid), a related NAD+ pathway compound, carries a well-documented hepatotoxicity risk, particularly with extended-release formulations and doses above 2 g/day. The FDA label for extended-release niacin (Niaspan) requires monitoring of liver enzymes before therapy, every six to 12 weeks for the first year, and periodically thereafter. NMN and NR are not niacin, and the hepatotoxicity mechanism appears different, but the niacin experience is the strongest available warning analog for anyone with liver disease starting high-dose NAD+ pathway supplementation.

Women-Specific Physiology and NAD+ Metabolism

Sex differences in NAD+ biology are real and understudy. Here is a practical framework for thinking about NMN and NR across female life stages when hepatic function is a variable.

Reproductive Years and PCOS

PCOS is associated with NAFLD in approximately 55% of women with PCOS, making it one of the most common reasons a woman in her reproductive years might have mild hepatic impairment. NMN has been proposed as a metabolic aid in PCOS because of its potential effects on insulin sensitivity, but no PCOS-specific NMN trial exists. If you have PCOS with elevated liver enzymes, the starting dose should be 50 mg/day or lower, with baseline metabolic panel and repeat labs at four weeks.

Menstrual cycle phase also matters. Estrogen modulates SIRT1 activity, one of the key NAD+-dependent enzymes. Circulating NAD+ levels vary across the cycle in women, though the magnitude and clinical significance of this variation are not yet quantified in peer-reviewed human data. This gap is worth naming plainly: we do not have cycle-phase-stratified NMN pharmacokinetic data in women.

Perimenopause and Post-Menopause

This is the life stage most heavily marketed to for NMN and NR. The logic is coherent: NAD+ levels fall with age, the decline may be steeper in women after menopause given estrogen's role in SIRT1 regulation, and midlife women carry a rising burden of MASLD as estrogen-protective effects on hepatic fat distribution are lost. A 2023 analysis published in Menopause noted that NAD+ depletion in ovarian tissue may contribute to declining oocyte quality, though this is not directly applicable to exogenous NMN supplementation in post-menopausal women.

Post-menopausal women with MASLD are a group where the theoretical benefit of NAD+ repletion is highest and the hepatic impairment risk is most clinically relevant. A staged titration approach makes the most sense here:

1. Establish a baseline metabolic panel including ALT, AST, GGT, and bilirubin.
2. Start at 50 mg/day for two weeks.
3. Recheck liver enzymes at week four.
4. If enzymes are stable, increase to 100 mg/day and recheck at week eight.
5. Continue escalation in 100 mg increments no faster than every four weeks, up to a maximum of 300 to 500 mg/day in mild impairment.

Do not exceed 300 mg/day without hepatology input if you have Child-Pugh B or any documented fibrosis above F1.

Trying to Conceive and Fertility

Some fertility clinics have begun discussing NMN as an adjunct for women over 35 undergoing IVF, based on mouse data showing improved oocyte mitochondrial function. The relevant Zhang et al. (2023) animal study used NMN to partially restore oocyte quality in aged mice. There are no human RCT data on NMN for fertility. If you are trying to conceive and have any hepatic impairment, this is a decision requiring joint input from your reproductive endocrinologist and a hepatologist.

Pregnancy and Lactation Safety

NMN and NR are not established as safe in pregnancy. This section is not a soft disclaimer. It is a direct statement of the evidence gap.

No adequate, well-controlled studies of NMN or NR have been conducted in pregnant women. The FDA has not assigned a formal pregnancy category to these compounds because they are sold as dietary supplements, not approved drugs. This absence of a pregnancy category is not reassurance. It means no one has done the required safety studies.

What we know from animal data is limited. A 2021 study in PNAS found that NMN supplementation in pregnant mice improved placental function and fetal development in a model of maternal obesity. However, mouse placental physiology differs substantially from human placental physiology, and this cannot be treated as a safety endorsement.

Lactation

No human lactation transfer studies exist for NMN or NR. Nicotinamide as a compound does transfer into breast milk and is considered safe at dietary levels. High-dose supplementation with NAD+ precursors, however, has not been studied in lactating women. The LactMed database maintained by the NIH does not have a specific entry for NMN or NR as supplements. The NIH Office of Dietary Supplements notes that the recommended dietary allowance for niacin during lactation is 17 mg/day niacin equivalents, a figure orders of magnitude below the doses in NMN/NR RCTs.

The practical guidance: do not use NMN or NR while pregnant or breastfeeding without direct approval from your OB-GYN or maternal-fetal medicine specialist. If you are using NMN for fertility support and are attempting conception, discuss a planned discontinuation point with your care team before a positive pregnancy test.

Contraception Requirement

NMN and NR are not known teratogens in the way that, for example, isotretinoin or methotrexate are. No reliable contraception requirement exists based on current evidence. But given the complete absence of human pregnancy safety data and the hepatotoxicity analog from high-dose niacin, women with hepatic impairment who are sexually active should discuss their family planning timeline with their prescriber before starting NMN or NR at doses above dietary supplement levels.

Who This Is Right For and Who Should Wait

Not every woman with liver disease needs to avoid NMN and NR entirely. The decision depends on the degree of impairment, the reason for supplementation, and what other treatments are in play.

Reasonable candidates for cautious titration

• Post-menopausal women with mild MASLD (Child-Pugh A, ALT less than two times the upper limit of normal) who have discussed this with a hepatologist
• Women with PCOS and mild hepatic steatosis who are not on hepatotoxic medications and have stable liver enzymes at baseline
• Women who have had a hepatitis flare that is now in remission, with normal or near-normal liver enzymes for at least six months

Women who should wait or avoid

• Anyone with active hepatitis (viral or autoimmune) with rising transaminases
• Women with Child-Pugh B or C cirrhosis
• Women with a history of drug-induced liver injury (DILI), particularly from dietary supplements
• Pregnant women, women actively trying to conceive without specialist input, and breastfeeding women
• Women taking other NAD+ pathway compounds simultaneously (e.g., high-dose niacin, high-dose B3 from multiple supplements) without pharmacist review

How to Monitor Safely: A Practical Lab Protocol

Because no formal monitoring guidelines exist for NMN or NR in hepatic impairment, the following is adapted from niacin monitoring guidance in the Niaspan prescribing information and general hepatotoxic supplement principles from ACOG's guidance on supplement safety.

| Timepoint | Tests | |---|---| | Baseline (before starting) | ALT, AST, GGT, total bilirubin, albumin, INR, metabolic panel | | Week 4 | ALT, AST | | Week 8 | ALT, AST, GGT | | Every 3 months thereafter | ALT, AST, GGT, metabolic panel |

Stop NMN or NR immediately and contact your provider if:

• ALT or AST rises above three times the upper limit of normal at any point
• You develop nausea, right-upper-quadrant pain, jaundice, or unusual fatigue
• Bilirubin rises without another explanation

These stopping rules are adapted from standard DILI assessment criteria used in supplement-related hepatotoxicity cases, as described in the NIH LiverTox database.

The Evidence Gap: What Women Are Missing

The under-representation of women in NMN and NR trials is not a minor statistical footnote. It changes how confident we can be in applying published safety data to female readers of this article.

Across the six largest published NMN and NR RCTs, pooled female enrollment averaged approximately 38%, and none of the trials stratified outcomes by sex or menstrual status. No trial has enrolled women with PCOS-related hepatic steatosis. No trial has enrolled perimenopausal women with MASLD. The data on which all current dosing recommendations rest was generated almost entirely in healthy men and mixed-sex healthy adults.

As Dr. Rachel Goldberg, reviewing clinician for this article, notes: "Women asking about NMN titration in liver disease deserve a straight answer, and the straight answer is that we are working from pharmacokinetic extrapolation, not female-specific hepatic impairment data. That should inform the caution you bring to dosing, not just the enthusiasm you feel about NAD+ biology."

This gap is not unique to NMN. The NIH Office of Research on Women's Health has documented chronic under-enrollment of women in supplement and metabolic trials broadly. Until female-specific hepatic pharmacokinetic studies are published, every NMN and NR dose recommendation for a woman with liver disease is an educated extrapolation. Treating it as anything more precise would misrepresent the science.

Interaction Checklist for Women With Hepatic Impairment

Women with liver disease are rarely on only one medication. Before starting NMN or NR, review this interaction list with your pharmacist.

• Metformin: Commonly used in PCOS with NAFLD. NMN may enhance AMPK activation similarly to metformin; the combination has not been studied for additive glucose-lowering effects in humans.
• Hormonal contraceptives: Estrogen-containing contraceptives are metabolized hepatically and increase hepatotoxicity risk in moderate-to-severe liver disease. Adding any hepatically-processed supplement in this context requires careful risk assessment.
• Tamoxifen: Used in premenopausal breast cancer and metabolized by CYP2D6, which is hepatically expressed. NAD+ pathway effects on CYP enzyme activity are not well characterized.
• Acetaminophen: Routine use at even standard doses stresses glutathione reserves in impaired livers. Combined with NAD+ precursor methylation demands, the cumulative burden on a compromised liver deserves attention.
• Statins: Statin-associated liver enzyme elevation occurs in approximately 1 to 3% of users. Monitoring becomes more complex when NMN or NR is added to a statin regimen in a woman with pre-existing liver disease.

Titration Summary Table

| Child-Pugh Class | Starting Dose | Escalation Interval | Max Dose Without Hepatology Input | |---|---|---|---| | A (mild) | 50 mg/day | Every 2 weeks | 300 mg/day | | B (moderate) | Defer to hepatologist | Monthly if approved | 50-100 mg/day only | | C (severe) | Not recommended | Not applicable | Not applicable |

All escalations assume stable liver enzymes at each checkpoint. Any rise in ALT or AST above two times baseline warrants stopping and reassessing.